Tracking and Exploring the Source of Viral REbound

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03117985

Acronym

TESOVIR

Enrollment

Registered

2017-04-18

Start date

2017-02-13

Completion date

2019-04-29

Last updated

2022-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hiv

Keywords

HIV reservoirs, HIV persistence, Viral rebound

Brief summary

Phylogenic analysis of viruses hosted in marker positive reservoir cells including CD32a+ CD4 T lymphocytes and rebounding viruses after treatment interruption

Interventions

OTHERno drug

Stopping antiretroviral therapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* \- Age\>18year old * Nadir CD4\>200/mm3 * CD4/CD8 ratio\> 0.5 * Continuous antiretroviral therapy for more than 2 years * Plasma Human Immunodeficiency Virus (HIV) 1 Ribonucleic acid (RNA) \<50 copies/ml in the last 2 years * Viral Load (VL)\<20copies at inclusion * Patients who are willing to participate and who understand the trial (particularly, the obligation to have protected intercourse during the study). * Informed consent * Short half-life treatment * Health insurance * A subset of CD4 (T4cells) express CD32a.

Exclusion criteria

* \- Acquired Immune Deficiency Syndom (AIDS) * Pregnancy * Human immunodeficiency virus (HIV)-2 co infection * Thrombopenia * Neurological events during primary infection * Hepatitis B + (HBV+) * Hepatitis C + (HCV+) * Cancer during the last 5 years. * Life expectancy \< 12 months * Autoimmunity * Acute infectious disease in the last 60 days. * Hemoglobin\<7g/dl * Glomerular filtration \< 60ml/min * Refusing protected intercourse * Risk of HIV transmission * Psychiatric disorders. * Alcool and drug abuse * Involvement in another clinical trial evaluating a therapeutic. * Being under tutorship * Being deprived of liberty

Design outcomes

Primary

Measure	Time frame	Description
Genetic Cartography	Week 1	Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026